NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Wednesday. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

NeuroMetrix stock opened at $4.05 on Wednesday. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73. The firm has a fifty day moving average price of $4.00 and a two-hundred day moving average price of $3.87. The firm has a market cap of $8.26 million, a price-to-earnings ratio of -0.88 and a beta of 2.20.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The business had revenue of $0.59 million for the quarter. During the same period in the previous year, the company earned ($1.66) earnings per share.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.